Kardigan's IPO Plans: Fueling the Next Wave of Cardiovascular Drug Development
Decision brief
Answer first · skim in under a minute
Cardiovascular drug developer Kardigan is gearing up for an IPO on the Nasdaq Global Market to finance the late-stage development of its pipeline, including danicamtiv for genetic dilated cardiomyopathy. This move signals a potential uptick in biotech IPOs as the market becomes more discerning.
Kardigan raised $460 million in a June 22, 2026 IPO to fund late-stage heart disease drugs—danicamtiv for genetic dilated cardiomyopathy and ataciguat for calcific aortic valve stenosis—after filing its S-1 on May 26.
Contents10 sections
Key Takeaways
- S-1 filed May 26, 2026 (SEC Accession 0001193125-26-239298); Reuters confirmed the U.S. IPO filing and KARD ticker plan.
- IPO close: 28,750,000 shares at $16.00; $460 million gross proceeds (Business Wire, June 22, 2026).
- Danicamtiv Phase 3 genetic/familial DCM study: NCT07210723.
- Ataciguat Phase 2/3 moderate CAVS study sponsored by Kardigan: NCT07001800.
What did Kardigan disclose when it filed for the IPO?
On May 26, 2026, Kardigan filed Form S-1 (Accession No. 0001193125-26-239298) with the SEC to register a Nasdaq Global Market listing.
Reuters reported the same day that the clinical-stage cardiovascular company planned ticker “KARD,” with J.P. Morgan, Jefferies, Leerink Partners, and TD Cowen as underwriters.
How large was the completed offering?
Kardigan’s June 22, 2026 Business Wire release said the IPO closed at 28,750,000 shares including the full 3,750,000-share underwriters’ option, priced at $16.00, for $460 million gross proceeds before discounts and expenses.
Common stock lists on the Nasdaq Global Market under KARD. Those figures are company-reported gross proceeds, not net cash after fees.
Which heart disease programs are the capital meant to advance?
Company materials and trial registries center on precision cardiovascular indications with limited approved options.
- Danicamtiv: oral cardiac myosin activator for genetic/familial dilated cardiomyopathy — see NCT07210723.
- Ataciguat: oral sGC activator for moderate calcific aortic valve stenosis — Kardigan-sponsored NCT07001800.
- Earlier exploratory danicamtiv DCM work is also archived as NCT04572893.
- Tonlamarsen for post-hospitalization acute severe hypertension appears in company pipeline descriptions but should be tracked via future registry updates.
How should BD teams read the heart disease IPO in 2026 context?
A $460 million gross raise is large for a clinical-stage cardiovascular specialist. Use of proceeds language in the S-1 and closing release points to clinical development and working capital, not commercial product sales.
Model dilution from the 28.75 million primary shares, then layer trial timelines from CT.gov rather than from banker roadshow adjectives. Heart disease programs still need randomized efficacy readouts before they change standards of care.
What remains unproven after the Kardigan listing?
IPO completion funds trials; it does not prove danicamtiv or ataciguat will meet primary endpoints. NCT07210723 and NCT07001800 status, enrollment, and endpoints should be re-checked before any launch forecast.
Secondary trading performance after debut is market color, not clinical evidence, and is omitted here unless sourced from an allowlisted filing.
How should heart disease BD teams stage diligence?
Stage one: lock the capital structure from the S-1 index and the June 22 closing release ($16 price, 28.75 million shares, $460 million gross). Stage two: pull protocol pages for NCT07210723 and NCT07001800 and copy primary endpoints into the model.
Stage three: separate genetic dilated cardiomyopathy from calcific aortic valve stenosis forecasts. They do not share the same specialists, imaging, or launch channels even though both sit under heart disease.
Stage four: wait for randomized data before assigning peak share. Public money improves survival odds for the company; it does not rewrite epidemiology or standard-of-care inertia in cardiomyopathy or valve disease.
Keep Reuters’ May 26 filing note beside the SEC index page in the diligence folder. That pairing shows both the market wire and the EDGAR primary for the same event. When the next protocol amendment posts on ClinicalTrials.gov, append it rather than overwriting the IPO capital facts.
Finally, treat heart disease as the indication family, not a single launch. Danicamtiv and ataciguat will need separate KOL maps, imaging partners, and payer dossiers even though one IPO financed both.
Related NovaPharma coverage
- Neurocrine Biosciences pipeline catalyst watch
- Vabysmo EU approval coverage
- Tillomed Laboratories pipeline update
Frequently Asked Questions
How large was Kardigan’s IPO for its heart disease pipeline?
Kardigan’s June 22, 2026 Business Wire release said the company closed an IPO of 28,750,000 shares at $16.00 per share, including the full underwriters’ option, for $460 million in aggregate gross proceeds, and lists on Nasdaq as KARD.
When did Kardigan first file to go public?
Kardigan filed a Form S-1 with the SEC on May 26, 2026 (Accession No. 0001193125-26-239298). Reuters reported the same-day U.S. IPO filing and proposed Nasdaq ticker KARD.
Which heart disease trials are on ClinicalTrials.gov?
Danicamtiv is listed in NCT07210723 for symptomatic genetic and familial dilated cardiomyopathy. Ataciguat is listed in NCT07001800, sponsored by Kardigan, for moderate calcific aortic valve stenosis.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
